Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
UCB Biopharma SRL
Alexa B Kimball; Gregor B E Jemec; Christopher J Sayed; Joslyn S Kirby; Errol Prens; John R Ingram; Amit Garg; Alice B Gottlieb; Jacek C Szepietowski; Falk G Bechara; Evangelos J Giamarellos-Bourboulis; Hideki Fujita; Robert Rolleri; Paulatsya Joshi; Pratiksha Dokhe; Edward Muller; Luke Peterson; Cynthia Madden; Muhammad Bari; Christos C Zouboulis